Nieuwe studie bewijst: ook profylactisch gebruik van hydroxychloroquine heeft geen enkel effect
13 August 2020
22:34
“Prophylactic use of hydroxychloroquine within four days after exposure did not decrease cumulative incidence of coronavirus disease 2019 (Covid-19).
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19). The rapid transmission and prevalence of the virus is accelerating the evaluation of existing medications to mitigate the infection such as hydroxychloroquine. Studies on the efficacy of hydroxychloroquine against Covid-19 focus on hospitalized patients with little consideration towards its preventative properties. As such, this study evaluated the potential for hydroxychloroquine to be used as postexposure prophylaxis to prevent symptomatic infection after Covid-19 exposure. The study determined the prophylaxis use of the medication did not prevent illness compatible with Covid-19 or confirmed infections compared to the placebo control group. This randomized trial was limited by the trial design, as it enrolled patients who were younger and healthier than the group at highest risk for severe Covid-19. The difference in the participant demographics may explain the lack of reported cardiac adverse events after hydroxychloroquine use. Nonetheless, this study was strengthened by the high medication adherence among trial participants.”
“We enrolled 821 asymptomatic participants. Overall, 87.6% of the participants (719 of 821) reported a high-risk exposure to a confirmed Covid-19 contact. The incidence of new illness compatible with Covid-19 did not differ significantly between participants receiving hydroxychloroquine (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); the absolute difference was −2.4 percentage points (95% confidence interval, −7.0 to 2.2; P=0.35). Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported.”
